Jan Marquard

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials

Julio Rosenstock, Jan Marquard, Lori M. Laffel et al. · Diabetes Care · 2018 · 339 citations

Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment

Jan Marquard, Silke Otter, Alena Welters et al. · Nature Medicine · 2015 · 161 citations

Biochemistry, Medicine, Insulin Management +9

Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial

Lori M. Laffel, Thomas Danne, Georgeanna J. Klingensmith et al. · The Lancet Diabetes & Endocrinology · 2023 · 98 citations · Full text

Metabolic Syndrome, Diabetes Management, Young People +11

Pharmacokinetic and pharmacodynamic profile of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial

Lori M. Laffel, William V. Tamborlane, Antoine Yver et al. · Diabetic Medicine · 2018 · 56 citations · Full text

Glucose metabolism and neurological outcome in congenital hyperinsulinism

Anja Ludwig, Katja Ziegenhorn, Susann Empting et al. · Seminars in Pediatric Surgery · 2010 · 44 citations

Metabolic Syndrome, Metabolic Disorder, Diabetes +6